{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"797","value":"195"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Interval from start of treatment to disease progression or death from any cause. Disease progression is defined as at least 20% increase in sum of longest diameter of target lesions or appearance of any new lesions. Subjective determination of significant worsening of disease-related symptoms was considered clinical disease progression","dispersionType":"Full Range","groups":[{"description":"All subjects who received at least one dose of temsirolimus at the MTD, 20 mg/M\\^2 plus liposomal doxorubicin were included.","id":"OG000","title":"Subjects Who Received Temsirolimus MTD, 20 mg/m^2"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Mean Progression Free Survival of Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2","type":"SECONDARY","unitOfMeasure":"Days"}